LATEST NEWS
News Releases
29 July 2025
NanoCell Announces Publication of Research Data in Journal for ImmunoTherapy of Cancer Demonstrating First-in-Class Non-Viral DNA-Based In Vivo CAR-T Generation
16 June 2025
NanoCell Secures Seed-Extension Financing from The Institute for Follicular Lymphoma Innovation to Advance Lead Clinical Candidate for B Cell Malignancies
4 February 2025
NanoCell Therapeutics Announces Upcoming Participation in Investor Conferences
8 November 2024
NanoCell Therapeutics Announces Animal Proof of Concept Data Demonstrating Non-viral DNA Delivery for In Vivo CAR-T Cell Generation
22 October 2024
NanoCell Therapeutics Announces Upcoming Participation in Investor and Scientific Conferences
16 May 2024
NanoCell Therapeutics Inc. and OneChain Immunotherapeutics S.L Announce Collaboration on In Vivo CAR-T Therapy for B-cell Lymphoma
19 March 2024
NanoCell Therapeutics Inc. Appoints Charles F. Albright, PhD, to its Scientific Advisory Board
26 September 2023
NanoCell Therapeutics Inc. Appoints Dr. Jacek Lubelski, PhD as Chief Technology Officer
3 August 2023
NanoCell Therapeutics Inc. Appoints Florence Salmon, PhD to its Scientific Advisory Board
4 January 2023
NanoCell Theapeutics Inc, in Consortium with Leading Research Organizations, Secures Multimillion Euro HORIZON-EIC Pathfinder Challenges Grant for Pioneering Gene Therapy Platform